This week’s directed reading hit home for me. Many autistic children have undergone genomic testing, which show hundreds of polymorphic variations that primarily inhibit the ability to detoxify, disrupt metabolic pathways, prevent pharmaceutical therapeutic response, and increase susceptibility to brain inflammation. These gene variants are common in the autistic population; however, the combination in which the present in each individual are often varied. I applaud the efforts of the National Institute of Environmental Health Sciences, primarily the director Dr. Linda S. Birnbaum who has been a close friend to the autism community and has worked tirelessly to find the epigenetic factors causing autism, which will aid in the recovery of our children who are disproportionately affected by a largely ignored epidemic by mainstream medicine.
I would like to share an article that I was directed to read this week. It included something that got me thinking regarding those with genetic susceptibility and mandatory vaccination.
individuals with heightened genetic sensitivities may seek protection under the Americans with Disabilities Act or state legislature protecting against genetic discrimination
Polymorphic variations in genes that reduce the ability to detoxify and increase the risk of inflammation is prevalent in autism. This may be an avenue to circumvent medical and religious vaccine waivers
I am sharing a training presentation that I organized as a course project in Patient Safety and Medical Error. I hope you enjoy! The PowerPoint is linked at the end.
It is estimated that 106,000 hospitalized patients have a fatal adverse drug reaction each year in the United States, and drug therapies are only moderately (25-60%) successful (Lazarou, Pomeranz, & Corey, 1998; Samer, Lorenzini, Rollason, Daali & Desmeules, 2013). Further, polymedication compounds the risk of iatrogenic disease (Vogt-Ferrier, 2011). Undoubtedly, there are multiplying reasons why these fatalities occur, which include (a) variable body composition and mass, (b) decreased ability for the liver to process drugs, (c) decreased ability of the kidneys to clear drugs, (d) increased sensitivity to drugs, (e) decreased blood-pressure-maintaining ability, (f) decreased temperature compensation, (g) diseases that affect drug response, (h) synergistic effects of drug interactions, and (i) inadequate FDA approval process (Public Citizen’s Health Research Group, n.d.).
Jain, A., Marxhall, J., Buikema, A., Bancroft, T., Kelly, J., Newschaffer, C. (2015). Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. Journal of the American Medical Association, 313(15). doi:10.1001/jama.2015.3077.
Theoharides, T., Konstantinos-Dionysios, A., Asimenia, A., Danae-Anastasia, D., Nikolaos, S., . . . & Kalogeromitros, D. (2012). Mast cells and inflammation. Biochimica et Biophysica Acta - Molecular Basis of Disease. Retrieved from http://www.sciencedirect.com/science/article/pii/S0925443910002929
Recent findings also indicate that mast cells have immunomodulatory properties. Understanding selective release of mediators could explain how mast cells participate in numerous diverse biologic processes, and how they exert both immunostimulatory and immunosuppressive actions. Unraveling selective mast cell secretion could also help develop unique mast cell inhibitors with novel therapeutic applications. This article is part of a Special Issue entitled: Mast cells in inflammation.
The emerging field of vaccine adverse event immunogenetics.